Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis.

Zhang S, Zhang XQ, Ding XW, Yang RK, Huang SL, Kastelein F, Bruno M, Yu XJ, Zhou D, Zou XP.

Br J Cancer. 2014 Apr 29;110(9):2378-88. doi: 10.1038/bjc.2014.127.

2.

Association between length of Barrett's esophagus and risk of high-grade dysplasia or adenocarcinoma in patients without dysplasia.

Anaparthy R, Gaddam S, Kanakadandi V, Alsop BR, Gupta N, Higbee AD, Wani SB, Singh M, Rastogi A, Bansal A, Cash BD, Young PE, Lieberman DA, Falk GW, Vargo JJ, Thota P, Sampliner RE, Sharma P.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1430-6. doi: 10.1016/j.cgh.2013.05.007.

PMID:
23707463
3.

Predictors for neoplastic progression in patients with Barrett's Esophagus: a prospective cohort study.

Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, van Vuuren AJ, Bode WA, van der Valk H, Ouwendijk RJ, Giard R, Lesterhuis W, Heinhuis R, Klinkenberg EC, Meijer GA, ter Borg F, Arends JW, Kolkman JJ, van Baarlen J, de Vries RA, Mulder AH, van Tilburg AJ, Offerhaus GJ, ten Kate FJ, Kusters JG, Kuipers EJ, Siersema PD.

Am J Gastroenterol. 2011 Jul;106(7):1231-8. doi: 10.1038/ajg.2011.153.

PMID:
21577245
4.

Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.

Verbeek RE, van Oijen MG, ten Kate FJ, Vleggaar FP, Schipper ME, Casparie MK, van Baal JW, Siersema PD.

Am J Gastroenterol. 2012 Apr;107(4):534-42. doi: 10.1038/ajg.2011.459.

PMID:
22270082
5.

Serum 25-Hydroxyvitamin D Levels and the Risk of Dysplasia and Esophageal Adenocarcinoma in Patients with Barrett's Esophagus.

Thota PN, Kistangari G, Singh P, Cummings L, Hajifathalian K, Lopez R, Sanaka MR.

Dig Dis Sci. 2016 Jan;61(1):247-54. doi: 10.1007/s10620-015-3823-5.

PMID:
26233550
6.

Risk for esophageal neoplasia in Barrett's esophagus patients with mucosal changes indefinite for dysplasia.

Horvath B, Singh P, Xie H, Thota PN, Allende DS, Pai RK, Patil DT, Plesec TP, Goldblum JR, Liu X.

J Gastroenterol Hepatol. 2015 Feb;30(2):262-7. doi: 10.1111/jgh.12696.

PMID:
25087917
7.

Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.

Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, Singh M, Singh V, Chuang KY, Boolchand V, Gavini H, Kuczynski J, Sud P, Reddymasu S, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Lieberman DA, Sampliner RE, Sharma P.

Clin Gastroenterol Hepatol. 2011 Mar;9(3):220-7; quiz e26. doi: 10.1016/j.cgh.2010.11.008.

PMID:
21115133
8.

Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.

Wang F, Lv ZS, Fu YK.

Dis Esophagus. 2011 Jul;24(5):318-24. doi: 10.1111/j.1442-2050.2010.01153.x. Review.

PMID:
21166737
9.

A Barrett's esophagus registry of over 1000 patients from a specialist center highlights greater risk of progression than population-based registries and high risk of low grade dysplasia.

Picardo SL, O'Brien MP, Feighery R, O'Toole D, Ravi N, O'Farrell NJ, O'Sullivan JN, Reynolds JV.

Dis Esophagus. 2015 Feb-Mar;28(2):121-6. doi: 10.1111/dote.12166.

PMID:
24428806
10.

Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.

Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG, Desai TK.

Gastrointest Endosc. 2014 Jun;79(6):897-909.e4; quiz 983.e1, 983.e3. doi: 10.1016/j.gie.2014.01.009. Review.

PMID:
24556051
11.

Risk of neoplastic progression in Barrett's esophagus diagnosed as indefinite for dysplasia: a nationwide cohort study.

Kestens C, Leenders M, Offerhaus GJ, van Baal JW, Siersema PD.

Endoscopy. 2015 May;47(5):409-14. doi: 10.1055/s-0034-1391091.

PMID:
25521571
12.

Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus.

Nguyen DM, Richardson P, El-Serag HB.

Gastroenterology. 2010 Jun;138(7):2260-6. doi: 10.1053/j.gastro.2010.02.045.

13.

Utility of confocal laser endomicroscopy in identifying high-grade dysplasia and adenocarcinoma in Barrett's esophagus: a systematic review and meta-analysis.

Gupta A, Attar BM, Koduru P, Murali AR, Go BT, Agarwal R.

Eur J Gastroenterol Hepatol. 2014 Apr;26(4):369-77. doi: 10.1097/MEG.0000000000000057. Review.

PMID:
24535597
14.

Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study.

Nguyen T, Duan Z, Naik AD, Kramer JR, El-Serag HB.

Gastroenterology. 2015 Nov;149(6):1392-8. doi: 10.1053/j.gastro.2015.07.009.

PMID:
26208896
15.

Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.

Visrodia K, Iyer PG, Schleck CD, Zinsmeister AR, Katzka DA.

Dig Dis Sci. 2016 Jan;61(1):158-67. doi: 10.1007/s10620-015-3697-6.

16.

Esophageal Adenocarcinoma and Its Rare Association with Barrett's Esophagus in Henan, China.

Liu S, Dai JY, Yao L, Li X, Reid B, Self S, Ma J, Chang Y, Feng S, Tapsoba Jde D, Sun X, Sun X.

PLoS One. 2014 Oct 15;9(10):e110348. doi: 10.1371/journal.pone.0110348. Erratum in: PLoS One. 2015;10(4):e0127135. de Dieu Tapsoba, Jean [corrected to Tapsoba, Jean de Dieu].

17.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group..

Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036.

PMID:
21878200
18.

Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else?

Pondugula K, Wani S, Sharma P.

Curr Gastroenterol Rep. 2007 Dec;9(6):468-74. Review.

PMID:
18377797
19.

Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett's Esophagus.

Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Muthusamy VR, Chmielewski GW, Corbett FS, Camara DS, Lightdale CJ, Wolfsen H, Chang KJ, Overholt BF, Pruitt RE, Ertan A, Komanduri S, Infantolino A, Rothstein RI, Shaheen NJ.

Gastroenterology. 2015 Dec;149(7):1752-1761.e1. doi: 10.1053/j.gastro.2015.08.048.

20.

Phase I and II enzyme polymorphisms as risk factors for Barrett's esophagus and esophageal adenocarcinoma: a systematic review and meta-analysis.

Bull LM, White DL, Bray M, Nurgalieva Z, El-Serag HB.

Dis Esophagus. 2009;22(7):571-87. doi: 10.1111/j.1442-2050.2009.00947.x. Review.

Supplemental Content

Support Center